The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research
  • last month
Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics, was recently a guest on Benzinga's All-Acess.

Candel is a clinical-stage biopharmaceutical company focused on developing immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has two main platforms that are currently undergoing clinical trials.

Candel also has its enLIGHTEN™ program, a systematic, iterative discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.